Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Associate Editor for Breast Cancer at ESMO Open, shared a post on X:
“Positive results from the phase 3 evERA trial: we may finally have an oral SERD plus everolimus combination available for the 2nd line treatment of HR+/HER2- MBC. Full extent of benefit in ESR1m vs ITT to be determined.”
More Posts Featuring P. Tarantino.